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Nucleophosmin (NPM) is a nucleolar phosphoprotein that binds the tumor suppressors p53 and p19Arf and
is thought to be indispensable for ribogenesis, cell proliferation, and survival after DNA damage. The NPM
gene is the most frequent target of genetic alterations in leukemias and lymphomas, though its role in
tumorigenesis is unknown. We report here the first characterization of a mouse NPM knockout strain. Lack
of NPM expression results in accumulation of DNA damage, activation of p53, widespread apoptosis, and
mid-stage embryonic lethality. Fibroblasts explanted from null embryos fail to grow and rapidly acquire a
senescent phenotype. Transfer of the NPM mutation into a p53-null background rescued apoptosis in vivo and
fibroblast proliferation in vitro. Cells null for both p53 and NPM grow faster than control cells and are more
susceptible to transformation by activated oncogenes, such as mutated Ras or overexpressed Myc. In the
absence of NPM, Arf protein is excluded from nucleoli and is markedly less stable. Our data demonstrate that
NPM regulates DNA integrity and, through Arf, inhibits cell proliferation and are consistent with a putative
tumor-suppressive function of NPM.
Nucleophosmin (NPM; also known as B23, NO38, or
numatrin) is an abundant and ubiquitously expressed nucleolar
phosphoprotein which has been implicated in ribosome bio-
genesis (41). Indeed, NPM binds nucleic acids (11), associates
with maturing preribosomal ribonucleoprotein particles (27),
and possesses intrinsic RNase activity (33) and its down-regu-
lation retards the processing of pre-rRNA (18). NPM acts as a
molecular chaperone (36) and shuttles between the nucleus
and cytoplasm (3), suggesting that it may also prevent aggre-
gation of nucleolar proteins and facilitate nuclear export.
NPM has the additional property of regulating cell prolifer-
ation, though its specific effect remains controversial. Down-
regulation of NPM in normal or immortalized cells delays cell
division (6) or induces apoptosis (18), while its overexpression
induces growth arrest in normal cells (9, 18) and stimulates
S-phase entry in immortalized cells (18). The level of NPM
protein increases when cells are induced to proliferate (15) and
decreases when they differentiate (17).
NPM has also been implicated in the acute response of
mammalian cells to environmental stresses, particularly DNA-
damaging agents. UV light, for example, induces up-regulation
(39) and nuclear relocalization of NPM (22) that, under these
experimental conditions, stimulates DNA repair and reduces
apoptosis (40).
NPM is part of a high-molecular-weight complex and phys-
ically interacts with many cellular proteins, including p53 (9),
Mdm2 (22), and Arf (2, 18, 20). p53 is a tumor suppressor that
is mutated in more than 50% of human cancers and accumu-
lates in response to DNA damage and oncogene activation
(16). When stabilized and activated, p53 initiates a transcrip-
tional program that leads to either cell cycle arrest or apoptosis
(37). The stability of the p53 protein is primarily regulated by
Mdm2, a ubiquitin E3 ligase, and Arf (p19Arf in the mouse and
p14Arf in humans), a nucleolar protein that binds p53 and
antagonizes Mdm2’s ubiquitin ligase activity for p53 (32). De-
spite several reports, it remains unclear whether interactions of
NPM with p53, Mdm2, and Arf underlie the effects of NPM on
ribogenesis, cellular growth, and survival.
NPM increases the stability and transcriptional activity of
p53, likely through multiple mechanisms, including its chaper-
one activity on p53, inhibition of the Mdm2 ubiquitin-ligase
activity, and competition with p53-Mdm2 binding (9, 22).
Other laboratories, however, using different cell systems and
experimental approaches, have reported an inhibitory effect of
NPM on phosphorylation of p53 and attenuation of its tran-
scriptional effects (23).
The Arf-NPM interaction seems to be critical in regulating
the stability of both proteins. Arf, in fact, induces polyubiquiti-
nation and degradation of NPM and inhibits its effects on
ribogenesis (18). NPM, instead, protects Arf from degradation
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and, surprisingly, antagonizes its ability to inhibit cell division
(20).
The effects of NPM on the Arf-Mdm2-p53 tumor suppressor
pathway, as well as its activities on ribogenesis, cell division,
and survival, might be relevant for the role of NPM in human
cancer. NPM, in fact, is frequently overexpressed in tumors of
different origin (8, 25) and is the most frequent target of
genetic alterations in hematopoietic tumors: it is rearranged
with the ALK gene in the majority of anaplastic large-cell
lymphomas (24) and is mutated in 35% of acute myeloid leu-
kemias (13). The biological contribution of NPM mutant al-
leles to transformation and the underlying molecular mecha-
nisms remain, however, undetermined.
To investigate the physiological function of NPM we have
generated and analyzed a mouse line null for the expression of
NPM. Our investigations shed a new light on the genetic and
functional interactions of NPM with p53 and Arf and provide
the first interpretation of the biological activity of cancer-as-
sociated NPM mutants.
MATERIALS AND METHODS
Generation of NPM-deficient mice. NPM-deficient mice were generated by
Lexicon Genetics Inc. (The Woodlands, TX). An embryonic stem (ES) cell clone
with a single gene trap event in the NPM locus was used to generate the
NPM-deficient mouse line (genetic background: C57BL/6  129/Ola) (43). The
vector used to create this particular ES cell clone was VICTR37 (8.1 kb) con-
taining a splicing acceptor site, an internal ribosome entry site-BGeo cassette for
positive selection, and the splice donor site of the first exon of the BTK gene. The
insertion was determined by genomic PCR and occurred 488 bp downstream of
exon I (AACCTACAGGTGGGGTCTTTCA*GTCCGAGCAGGCGCCCTGAGG;
the retroviral long terminal repeat sequence is underlined, and the asterisk
indicates the insertion site).
PCR genotyping. A PCR-based strategy was developed to distinguish wild-type
and mutant NPM alleles. The following primers were used: 5-TAGAAGCAG
CGGCCTGAACACTA; 5GATGCTGACTCCGCCTACCAGA; and 5-GCCT
TGCAAAATGGCGTTACTT (see Fig. 1A). A 336-bp fragment indicates the
presence of the mutated allele, whereas a 641-bp fragment is amplified from the
wild-type allele (see Fig. 1B). Trp53 genotyping was determined as previously
described (19)
Histology. For sectioning, embryos were fixed in 4% paraformaldehyde
1-phosphate-buffered saline overnight, embedded in paraffin, sectioned, and
stained in hematoxylin and eosin.
Immunohistochemistry. For bromodeoxyuridine (BrdU) experiments, preg-
nant females were injected intraperitoneally with 150 g of BrdU/g of body
weight and sacrificed 2 h later. The following antisera were used: anti-BrdU
(1/200; Boehringer Mannheim), anti-cleaved caspase 3 (1/200; Cell Signaling),
anti-NPM (NPMc) (10), anti-H2AX (1:100; Upstate), and anti-p53 (monoclonal
antibody raised against mouse p53 protein, clone AI25, kindly provided by
Kristian Helin) An appropriate biotinylated secondary antibody was then applied
to the slides. Avidin-conjugated peroxidase (ABC and DAB kits from Vector
Laboratories) was used for immunostaining.
TaqMan real-time quantitative reverse transcription-PCR assays. Total RNA
(1 g) was reverse transcribed in a final volume of 20 ul using a commercial kit
(Gibco-BRL). The quantitative PCR assays were performed following the man-
ufacturer’s specifications (PE Applied Biosystems). Primer pairs and TaqMan
probes were designed by Applied Biosystems. Each sample was analyzed in
triplicate.
Immunoblotting and immunoprecipitation. Western blot experiments were
performed as described (9). The primary antibodies used were: sheep polyclonal
anti-p53 (1:1000; Ab7; Oncogene); rabbit polyclonal anti-p53 phospho-Ser15
(1/1,000; Cell Signaling), monoclonal anti-p21 (1/300; F5; Santa Cruz); poly-
clonal anti-p19Arf (1:1,000; Abcam); monoclonal anti-NPM (NPMc; NPMa)
(10); polyclonal anti--tubulin (1:1,000, H-235, Santa Cruz); monoclonal antiv-
inculin (1:1,000; hVIN-1; Sigma), monoclonal anti-Flag (1:1,000; Sigma), poly-
clonal anti-NPM (B19) (9), and anti-H2AX (1:1,000; Upstate)
Immunofluorescence. Immunofluorescence analysis was performed as previ-
ously described (9). The antibodies used were polyclonal anti-p19Arf (1:200;
Abcam); monoclonal anti-NPM (NPMc), monoclonal antinucleolin (1:500;
MS-3; Santa Cruz); polyclonal antifibrillarin (1:300; A-16; Santa Cruz), anti-
phosphorylated ATM (1:500; Rockland), and anti-H2AX (1:300; Upstate).
Cell culture, transfection, and infection. Mouse embryo fibroblasts (MEFs),
Phoenix, and 293T cells were cultured at 37°C and 5% CO2 in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum. Transient
transfections were performed using the standard calcium phosphate precipitate
method for Phoenix and 293T cells and FuGENE 6 (Roche) for MEFs. For
infection experiments, we used a Pinco-based vector expressing either only the
green fluorescent protein (GFP) or GFP-tagged wild-type NPM and mutant
protein. For expression of RasV12, c-myc, and p19Arf we used the pBabe retro-
viral vector carrying puromycin resistance. For interference experiments we used
a lentivirus-based vector called Lentilox3.7 (31). Empty or recombinant retrovi-
ral or lentivirus vectors were transfected into the Phoenix and 293T packaging
cell lines, respectively, and after 48 h the supernatants were used to infect target
cells.
Cell cycle analysis. Replicative DNA synthesis and DNA content were ana-
lyzed using bivariate flow cytometry. Experiments have been carried out as
described previously (9). Briefly, cells were pulsed with BrdU 1 M, fixed and
treated with 2 M HCl for 20 min followed by 2 volumes of 0.1 M sodium borate
(pH 8.5). After washing cells were incubated with anti-BrdU antibody for 1 hour,
washed and incubated with fluorescein isothiocyanate-conjugated secondary an-
tibody. Cells were counterstaining overnight with 5 g/ml propidium iodide.
Plasmids. For short interfering RNA we used a lentivirus-based vector (Len-
tilox 3.7), in which we cloned (HpaI-XhoI cloning sites) the following double-
stranded oligonucleotides. For NPM interference we used two different double-
standard oligonucleotides that targeted two different regions of NPM mRNA
(for region 1, FW 5TggctgacaaagactatcacTTCAAGAGAgtgatagtctttgtcagccTT
TTTTC and REV 5TCGAGAAAAAAggctgacaaagactatcacTCTCTTGAAgtgat
agtctttgtcagccA; for region 2, FW 5TgagcaccagttgtcattaaTTCCAAGAGAttaa
tgacaactggtgcAcTTTTTTC and REV 5TCGAGAAAAAAgagcaccagttgtcattaa
TCTCTTGGAAttaatgacaactggtgcAcA). Lowercase letters represent the region
that matches with the sequence of the targeted gene, and uppercase letters
represent the common part of the oligonucleotides required for cloning and
hairpin formation.
Analysis of newly synthesized rRNA. Experiments have been performed as
previously described (2). Briefly, cells were labeled with 2.5 uCi of [3H]uridine
per ml in complete medium for 30 min, washed twice, and then incubated in
complete medium without the radioactive precursor for 2 h. Total RNA was
isolated with Trizol (Invitrogen), quantitated, and loaded into 1% agarose gels
containing formaldehyde. After electrophoretic separation the RNA was trans-
ferred to Hybond N membranes (Amersham), and dried membranes were
treated with En3Hance (Perkin Elmer) and then subjected to autoradiography.
Yolk sac cell preparation. The yolk sac was dissected from 10.5-day embryos,
rinsed to remove maternal blood, and incubated with 0,1% collagenase (Sigma)
in 20% fetal bovine serum for 45 min at 37°C. Dispersed yolk sac was drawn
through a 70-um strainer and washed with Iscove’s minimal medium plus 10%
fetal bovine serum. The cell suspension was counted and seeded in semisolid
medium 3236 (StemCell Technologies) supplemented with 15% fetal bovine
serum, 100 ng/ml stem cell factor, 5 ng/ml interleukin-3 and interleukin-6. After
10 days colonies can be counted and collected cells are replated. After the first
replating the cell population have been cultured both in semisolid or liquid
(Dulbecco’s modified Eagle’s medium) medium.
RESULTS
Mid-stage embryonic lethality of NPM/ embryos. An ES
cell clone with a specific gene trap event in the NPM locus was
microinjected into host blastocysts to produce an NPM gene
trap mouse line (43). The insertion gene trap vector, based on
Moloney murine leukemia virus, integrated between exon 1
and exon 2 of the NPM locus (Fig. 1A). Mice heterozygous for
this mutation were viable and fertile. However, matings be-
tween heterozygous animals produced no viable homozygous
mutant offspring (F2 in Table 1), indicating a recessive lethal
phenotype (see Fig. 1B for representative genotypes and West-
ern blots of wild-type and mutated NPM tissues).
Closer inspection revealed that all homozygous embryos
(NPM/) died in utero between 9.5 and 10.5 days postcoitum
(dpc) (Table 1) and exhibited marked growth deficiency and
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FIG. 1. Gene trap event in the NPM locus leads to a null NPM mutation and early embryonic lethality in mice. (A) Schematic representation
of the targeting retroviral construct (middle) and the wild-type (upper) or mutated (lower) NPM alleles. Positions of oligonucleotides used for the
PCR-based genotyping (see panel B) are indicated by arrows (a, b, and c). LTR: long terminal repeats; SA: splicing acceptor site; SD: splicing
donor sites; -Geo: neomycin resistance gene. (B) Left panel: PCR analysis of embryos with the indicated NPM genotypes (primer pairs used are
indicated on the right). Right panel: expression of NPM protein as determined by Western blotting of lysates prepared from whole embryos. A
polyclonal antibody anti-NPM (Santa Cruz) was used. (C) Wild-type (WT) and knockout (KO) NPM embryos at 10.5 dpc of embryonic
development (upper panels) and immunohistochemistry analysis of NPM expression in neuroepithelial (NE) sections from the same embryos,
using NPMc antibodies (lower panels). (D and E) immunohistochemistry analysis of apoptosis (D; anti-caspase-3 staining) and p53 expression
levels (E; anti-p53 staining) in the developing neuroepithelium and dorsal root ganglia (DRG) of wild-type NPM and knockout 10.5 dpc embryos.
(F and G) Expression of p53 target genes analyzed by quantitative PCR (p21, Pig8, Mdm2, and Bax) using mRNA from wild-type NPM (black bars),
heterozygous (white bars), and knockout (gray bars) embryos. (G) Western blotting analysis of p21 protein expression in total embryo lysates.
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gross developmental alterations (Fig. 1C). Histological exam-
ination of various embryonic tissues from NPM/ mutants
did not reveal developmental features characteristic of their
embryonic stage, suggesting that the growth defect is due to a
developmental arrest (Fig. 1C, representative sections of neu-
roepithelium from wild-type and null 10.5 dpc embryos; see
also Fig. S1 in the supplemental material). No viable mutants
were observed beyond embryonic day E10.5 (Table 1). Con-
sistent with an overall impact of the mutation throughout the
whole embryo at 9.5 to 10.5 dpc, NPM was highly and ubiqui-
tously expressed at this developmental stage, as demonstrated
by immunohistochemistry (Fig. 1C). The placental structures
of NPM/ embryos were smaller but normally developed (not
shown).
p53-dependent apoptosis in the NPM/ embryos. To in-
vestigate the cellular basis of the embryonic lethality associated
with the NPM mutation, we investigated the effect of NPM
expression on apoptosis by measuring in situ activation of
caspase-3 by immunohistochemistry. Caspase-3-positive cells
were only occasionally observed in wild-type embryos, as ex-
pected. In the mutant embryos, instead, caspase-3-positive
cells were present at a high proportion in all the tissues exam-
ined (Fig. 1D for representative results). To investigate the
molecular basis for the increased apoptosis in the NPM-null
embryos, we measured levels of p53 expression by immunohis-
tochemistry. Anti-p53 staining was low or undetectable in the
wild-type embryos, while a large number of p53-positive cells
were found in all NPM/ embryonic tissues (Fig. 1E for
representative results). Quantitative PCR and Western blot-
ting analysis of a number of p53 target genes (p21, Mdm2, pig8,
and Bax) confirmed the transcriptional competence of stabi-
lized p53 in the knockout embryo (Fig. 1F and G). It appears,
therefore, that p53 is constitutively activated in NPM/ em-
bryonic cells.
To investigate whether p53 activation is responsible for the
observed mid-stage embryonic lethality, widespread embryo
apoptosis, and in vitro MEF senescence, the NPM mutation
was transferred into a p53-null background (19). Matings be-
tween NPM/ and p53/ or p53/ mice produced no viable
doubly homozygous mutant offspring, indicating that the ab-
sence of p53 does not rescue embryonic lethality of the NPM
mutation (Table 2). Analysis of embryo development revealed
the presence of double-knockout embryos up to 12.5 dpc, a
stage when all NPM/ embryos have been readsorbed (Table
3). Moreover, the NPM/ p53/ (double-knockout) em-
bryos were bigger and more developed than NPM/ embryos
at the same developmental stage and more similar to their
p53/ controls (compare Fig. 2A with Fig. 1C). Analysis of
anti-caspase-3-positive cells revealed a marked reduction of
apoptotic cells in the double-knockout mutant compared to
NPM/ embryos (Fig. 2B). It appears, therefore, that loss of
p53 has a moderate effect on the mid-stage embryonic lethality
associated with mutation of NPM, while it rescues the apopto-
sis observed in vivo.
NPM/ cells can be grown in vitro only if p53 is lost
(double-knockout MEFS) or functionally inhibited (yolk sac
cells). We then tried to propagate in vitro fibroblasts from
NPM/ and wild-type embryos (MEFs). Upon seeding, the
fibroblasts adhered to the culture dishes, did not proliferate,
and acquired a senescence-like phenotype (not shown). This
experiment was performed several times using MEF prepara-
tions from NPM/ embryos at different stages (9, 10, and 10.5
dpc), and always gave the same result.
To investigate whether the growth arrest observed in
NPM/ MEFs is the direct consequence of NPM deficiency,
we down-regulated expression of NPM in growing wild-type
MEFs using lentivirus vectors expressing NPM-specific short
hairpin RNAs (siNPM). Expression of siNPM led to the almost
complete disappearance of the NPM protein in about 70% of
the infected cells, as evaluated by immunofluorescence analysis
(Fig. 2C). Western blot analysis of the same cell population
revealed a consistent decrease in cell proliferation of fibroblast
infected with the siNPM lentivirus (Fig. 2C). Analysis of BrdU
incorporation performed in the same experiment (day 3)
showed a dramatic decrease of BrdU-positive cells in the
MEFs infected with the siNPM lentivirus compared to control
cultures (from 27 to7% in the experiment shown in Fig. 2C).
Comparable results were obtained using lentivirus vectors that
expressed different NPM-specific short hairpin RNAs (not
shown; see Materials and Methods). It appears, therefore, that
TABLE 1. Genotype analysis of progeny from NPM heterozygous intercrosses
Stage No. of litters Total no. of embryos
No. of embryos with NPM
genotype: No. of abnormal embryosa NPM/ (%)b
/ / /
E9.5 1 12 4 6 2 2 17
E10.5 6 55 15 27 13 13 24
E11.5 2 16 7 9 0 0 0
E12.5 2 14 6 8 0 1 0
F2 30 142 54 88 0
a Number of embryos with a growth defect and/or gross abnormalities.
b Percentage of embryos with NPM/ genotype.
TABLE 2. Genotypes of mice from NPM/ p53/  NPM/
p53/ crosses
Genotype
No. of mice Total no.
of miceNPM/ NPM/ NPM/
p53/ 13 44 0 57
p53/ 24 60 0 84
p53/ 25 26 0 51
Total 62 130 0 192
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depletion of NPM expression in wild-type MEFs induces cell
cycle arrest, suggesting that the growth arrest observed with
NPM/ MEFs is a cell-autonomous effect due to NPM defi-
ciency.
Notably, wild-type MEFs infected with siNPM lentiviruses
expressed moderately higher protein levels of the p53 target
p21 compared to control cultures (Fig. 2C), suggesting that the
cell cycle arrest observed after NPM depletion is due to p53
activation. This hypothesis was confirmed by the finding that
MEFs derived from double-knockout embryos did not undergo
growth arrest in culture and showed unlimited growth poten-
tial (as evaluated by the 3T3 assay; not shown). The growth
properties of double-knockout MEFs are described below
(Fig. 4B).
Activation of p53 is antagonized by cytokines, as shown by
the finding that hematopoietic precursors grown in vitro in the
presence of cytokines are resistant to p53-induced apoptosis
(30). Therefore, we investigated whether NPM/ hematopoi-
etic cells can be propagated in vitro. Single-cell suspensions
from E9.5 to E10.5 yolk sacs were plated in methylcellulose in
the presence of cytokines and macroscopic colonies (CFC)
were scored after 14 days. Thereafter, single-cell suspensions
from pooled primary CFC colonies were replated into second-
ary CFC cultures or grown in liquid cultures.
As we had hypothesized, NPM/ yolk sac cells were able to
grow under both culture conditions (Fig. 2D, left panel, and
data not shown). On the contrary, 24 h of cytokine deprivation
provoked a marked reduction of the ability of NPM/ cells to
form CFCs, while had no effect on wild-type cells (Fig. 2D,
right panel). Reexpression of NPM in cytokine-deprived
NPM/ cells restored the normal levels of CFC colonies (Fig.
2D). It appears, therefore, that NPM/ yolk sac cells can be
propagated in vitro only if grown in the presence of cytokines.
Analysis of the number of CFC colonies, however, showed
that the efficiency of colony formation and growth rate of
NPM/ yolk sac cells (in the presence of cytokines) was
slightly, yet consistently, lower than that of control wild-type
cells (Fig. 2D, left panel, and data not shown); this lower
proliferation rate correlated with a moderate degree of p53
activation in the same cells. In fact, analysis of the status of p53
activity revealed a slight increase of p53 phosphorylation (Ser
18) and p21 expression in the NPM/ cultures (Fig. 2D,
middle panel). Notably, reexpression of NPM into NPM/
hematopoietic precursors (by retroviral gene transfer) reduced
levels of p53 phosphorylation and p21 expression and restored
the efficiency of colony formation (Fig. 2D). Together, these
findings indicate that NPM/ cells can be grown in culture
only if p53 is lost, as in the p53/ NPM/ MEFs, or func-
tionally inhibited, as occurs with NPM/ yolk sac cells when
grown in the presence of cytokines.
p53 activation in NPM/ cells is part of a DNA damage
response. We next investigated the mechanisms responsible for
p53 activation in NPM/ cells. It has been proposed that
NPM inhibits p53-dependent Arf activity by targeting it to
nucleoli, thus segregating Arf from p53 (20). To test whether
activation of p53 in NPM/ cells is due to Arf activation, we
down-regulated expression of NPM in Arf/ MEFs, using
lentivirus vectors expressing NPM-specific short hairpin
RNAs. Down-regulation of NPM expression in Arf/ cells
(Fig. 3A) led to increased p53 stabilization (Fig. 3A), accumu-
lation of p21 (Fig. 3A), and decreased cellular growth (Fig.
3B), demonstrating that Arf is not critical for activation of p53
following NPM depletion.
Activation of p53 is part of a checkpoint response to DNA
damage, which involves activation of ATM/ATR kinases, phos-
phorylation of a set of downstream targets, including histone
H2AX, and their accumulation at sites of DNA double-strand
breaks or stalled replication forks (14). Western blotting anal-
ysis of H2AX phosphorylation (-H2AX) in total embryo ly-
sates revealed higher level of -H2AX in the NPM/ samples
compared to wild-type samples (Fig. 3C). immunohistochem-
istry analysis of various embryo tissues confirmed markedly
increased -H2AX focus formation in the NPM/ samples
(Fig. 3D for representative sections). Likewise, Western blot-
ting (Fig. 3C) and immunofluorescence (Fig. 3E) experiments
revealed increased levels of -H2AX and -H2AX focus for-
mation in cultured NPM/ yolk cells compared to the wild-
type samples. Staining of yolk sac cells with antibodies against
phosphorylated ATM revealed the presence of phosphorylated
ATM foci in the NPM/ but not wild-type cells, which largely
colocalized with the -H2AX foci (Fig. 3F). Notably, reexpres-
sion of NPM in NPM/ yolk cells restored levels of -H2AX
and phosphorylated ATM foci to the background levels of
wild-type cells (Fig. 3F and 3C). It appears, therefore, that loss
of NPM leads to the constitutive activation of a DNA damage
response, suggesting that p53 activation in NPM/ cells is
secondary to the loss of a checkpoint function of NPM on
DNA integrity.
Increased cell proliferation in NPM/ embryos and dou-
ble-knockout MEFs. We then investigated the effects of NPM
expression on cellular proliferation by measuring BrdU incor-
poration in wild-type and NPM/ embryos and comparing the
growth properties of double-knockout and p53/ MEFs. To
analyze BrdU incorporation in embryos, 10.5 dpc pregnant
female mice were intraperitoneally injected with BrdU and
TABLE 3. Genotype analysis of progeny from NPM/ p53/  NPM/ p53/ intercrosses
Stage No. oflitters
Total no.
of embryos
No. of embryos with NPM genotype: No. of abnormal
embryosa NPM
/ (%)b
/ / /
E10.5 2 16 2 10 4 4 25
E11.5 2 33 8 20 5 5 15
E12.5 2 15 4 10 1 1 6
a Number of embryos with a growth defect and/or gross abnormalities.
b Percentage of embryos with NPM/ genotype.
8878 COLOMBO ET AL. MOL. CELL. BIOL.
FIG. 2. Loss of p53 gene rescues apoptosis in NPM knockout (KO) embryos. (A) p53/ and double-knockout (p53/ NPM/) embryos at
different stages of development (10.5 and 12.5 dpc). (B) Analysis of apoptosis in the developing neuroepithelium (NE) of wild-type (WT), NPM/,
p53/ and double-knockout embryos. Immunohistochemistry analysis was performed using anti-activated caspase-3 antibody and counterstained
with hematoxylin end eosin. (C) Down-regulation of NPM expression in wild-type MEFs by short interfering RNA. Cells were infected with a
control (CTRL) lentivirus or a lentivirus expressing short interfering RNA for NPM (siNPM), as indicated, and analyzed by immunofluorescence
using an anti-NPM antibody (NPMa) and by Western blot using anti-NPM and anti-p21 antibodies. For the growth curves, infected cells were
seeded on six-well plates at a density of 104 cells per well. Cultures were harvested every day, and the number of cells was determined. The numbers
refer to mean values of triplicate determinations. At day 3 of the growth curve, levels of BrdU incorporation were determined by FACS analysis
(results refers to mean values of triplicate determinations). (D) Left panel: 2,000 cells derived from the yolk sac of knockout and wild-type embryos
and knockout embryos reconstituted with GFP-NPM were seeded in semisolid medium supplemented with interleukin-3, interleukin-6, and stem
cell factor and scored after 10 days for number of colonies. Middle panel: expression of phosphorylated p53 (anti-Ser18) and its target p21 in yolk
sac-derived cells. Right panel: yolk sac-derived cells were cultured in suspension for 24 h, with (control) or without cytokines, and counted after
10 days (results are expressed as a percentage of the colonies obtained with control cells).
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FIG. 3. p53 activation in NPM null cells is part of a DNA damage response. (A) Western blots of lysates from the same cells as in panel B
analyzed with antibodies against NPM, p21, and p53. (B) Growth curves of Arf/ MEFs infected with a control lentivirus or a lentivirus expressing
short interfering RNA for NPM (siNPM); 2  104 cells were plated in six-well plates. Cultures were harvested every day, and the number of cells
was determined. The numbers refer to mean values of triplicate determinations. (C) Western blotting analysis of H2AX expression in lysates of
total embryo and yolk sac cells. (D) Analysis of H2AX expression in the developing brain of wild-type (WT) NPM and knockout (KO) 10.5 dpc
embryos. Embryo sections were stained with a monoclonal antibody against the phosphorylated form of H2AX and counterstained with
hematoxylin and eosin. (E and F) Immunofluorescence analysis of H2AX and phosphorylated ATM (p-ATM) expression in wild-type and
knockout yolk sac cells and in knockout cells reconstituted with GFP-NPM.
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sacrificed 45 min later. The recovered embryos were analyzed
for BrdU incorporation in situ by immunohistochemistry.
Microscopic examination of embryo sections from different
tissues revealed a random dispersion of BrdU-positive cells in
the mutant tissues, at variance with their normal counterparts,
where cycling and resting cells typically cluster within separate
areas (Fig. 4A for representative sections from neuroepithe-
lium and dorsal root ganglia). Analysis of the frequency of
BrdU-positive cells revealed a slightly yet consistently higher
number of cycling cells in the NPM/ samples than in the
wild-type counterparts (Fig. 4A). To obtain a quantitative es-
timate of BrdU positivity, we performed a FACS analysis of
cell suspensions obtained from wild-type and NPM/ em-
bryos of different stage (E9.5 and 10.5 dpc). The results
showed an approximately 45% increase of BrdU-positive cells
in NPM/ embryos (see Fig. 4A for representative results
obtained from 10.5 dpc embryos). Together, these data dem-
onstrate that NPM expression is not critical for cell cycle pro-
gression, as previously hypothesized (15), and that, on the
contrary, it negatively regulates progression through the cell
cycle.
Comparison of the growth properties of double-knockout
and p53/ MEFs revealed that double-knockout fibroblasts
grow markedly faster than p53/ controls (see Fig. 4B for one
representative curve). BrdU incorporation analysis performed
on logarithmically growing cell population revealed an approx-
imately 35% increase of BrdU-positive cells in the double-
knockout cells (Fig. 4B). It appears, therefore, that loss of
NPM expression correlates with increased proliferation both in
vivo and in cultured cells. In the latter, however, increased
proliferation can only be observed if p53 is lost, since the loss
of NPM is also responsible for the activation of a p53-depen-
FIG. 4. Loss of NPM leads to increased proliferation. (A) Left panel: immunohistochemistry analysis of proliferation (anti-BrdU staining) in
the developing neuroepithelium and dorsal root ganglia (DRG) of wild-type (WT) NPM and knockout (KO) 10.5 dpc embryos. Right panel:
evaluation of BrdU-positive cells in wild-type and knockout embryos through FACS analysis of cells derived directly from embryos after treatment
with 0.1% collagenase. (B) Right panel: growth curves of p53/ and double-knockout MEFs at passage 4 (2  104 cells were plated into six-well
plates). Cultures were harvested every day, and the total number of cells was determined. The numbers represent the mean values of triplicate
determinations. The experiment was repeated twice, using two independently derived MEF cultures, and gave comparable results. Left panels:
evaluation of BrdU-positive cells in growing p53/ and double-knockout MEFs. Bars represent mean values of triplicate determinations. The
experiments were repeated three times, giving comparable results.
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FIG. 5. Regulation of Arf stability and function by NPM. (A) Immunofluorescence analysis of p19Arf localization (red) in p53/ and
double-knockout (KO) MEFs. Nucleolin staining (green) was used as a marker for nucleoli. (B) Left panels: Western blotting analysis of p19Arf
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dent checkpoint. Whether, in the NPM/ fibroblasts, the in-
creased proliferation is responsible for the accumulation of
DNA replication alterations, which then activate a (p53-de-
pendent) intra-S-phase checkpoint (1) remains, however, to be
determined.
NPM is critical for the nucleolar localization and stability of
Arf protein. Arf inhibits cell proliferation through both p53-
dependent and -independent mechanisms (34). Since NPM
physically interacts with Arf and protects it from degradation
(20), the inhibitory effect of NPM on cellular proliferation
might be mediated by Arf itself. Therefore, we investigated the
effects of NPM on Arf expression. Immunofluorescence anal-
ysis of p53/ and p53/ NPM/ (double-knockout) MEFs
revealed that Arf, in the absence of NPM, is nuclear-diffuse
and completely excluded from nucleoli, which remain as intact
organelles, as shown by staining with other nucleolar markers,
such as nucleolin (Fig. 5A) and fibrillarin (not shown). Nota-
bly, Arf levels in the double-knockout MEFs were markedly
lower than in the control p53/ MEFs (Fig. 5B, left panel).
Reexpression of NPM in double-knockout cells restored nor-
mal levels (Fig. 5B), compared to p53/ cells, and nucleolar
localization of Arf (Fig. 5B).
Since levels of arf mRNA were comparable in the p53/
and double-knockout MEFs (Fig. 5C, left panel), we investi-
gated whether NPM regulates Arf stability. To this end, p53/
and double-knockout cells were exposed to 100 M cyclohex-
imide to inhibit de novo protein synthesis, harvested at serial
time points following treatment, and assessed for Arf levels by
Western blotting. The half-life of Arf in p53/ MEFs was
approximately 12 h (Fig. 5C, right panel). In the double-knock-
out cells the stability of the Arf protein was markedly reduced,
with a half-life of about 2 to 4 h (Fig. 5C, right panel). There-
fore, NPM is indispensable for the nucleolar localization of Arf
and critical for its stability. These data are consistent with
previous reports showing destabilization and partial delocaliza-
tion of Arf following down-regulation of NPM expression (20).
NPM is not a downstream target of Arf. Upon activation by
abnormally high thresholds of mitogenic signals, such as those
imposed by oncogenic Myc or Ras, Arf activates p53 via
Mdm2, enabling cells to stop proliferating (35). Arf can inhibit
ribogenesis (36) and, though less efficiently, suppress prolifer-
ation of cells that lack both p53 and Mdm2, implying interac-
tion with other regulators (39). Due to its reported properties
of stimulating the cell cycle and ribogenesis, NPM has been
proposed as a critical downstream target of Arf (18). Upon
activation, Arf would bind NPM directly, thus inducing its
degradation or blocking its nucleus-cytoplasm shuttling activity
(7). Therefore, we evaluated the effects of NPM on the ability
of Arf to inhibit cellular growth and ribosome biogenesis in
p53/ cells.
p53/ and double-knockout MEFs infected with control or
Arf-expressing retroviruses were analyzed for proliferation ca-
pacity or labeled with [3H]uridine in order to evaluate newly
synthesized rRNA. Exogenously expressed Arf localized pre-
dominantly within nucleoli in the p53/ MEFs, as expected
(not shown), while it was nuclear diffuse and mainly excluded
from nucleoli in the double-knockout cells (Fig. 5D). Consis-
tent with the observed effect of NPM on Arf stability, levels of
exogenous Arf were lower in double-knockout than in p53/
cells (Fig. 4D). The ability of overexpressed Arf to reduce cell
proliferation was comparable in p53/ and double-knockout
MEFs (Fig. 5D). Notably, the proliferation rate of the various
MEF populations (controls and p19Arf infected) nicely corre-
lated with the levels of p19Arf (Fig. 4D). As an example, p19Arf-
infected double-knockout cells and p53/ control cells ex-
pressed comparable levels of p19Arf and showed similar growth
rates (Fig. 5D). Finally, the ability of overexpressed Arf to
reduce maturation of the 28S rRNA was comparable in p53/
and double-knockout MEFs (Fig. 5E). The effect of NPM
expression on rRNA processing was also negligible under basal
conditions (Fig. 5E). It appears, therefore, that expression of
NPM is not rate limiting for rRNA processing and that the
ability of ectopically overexpressed Arf to inhibit ribogenesis
and cellular proliferation (in the absence of p53) is indepen-
dent of NPM and its nucleolar localization.
NPM regulates the biological activities of Arf. Mitogenic
stimuli, as imposed by enforced expression of c-Myc or the
RasV12 mutant, induce expression of Arf, which leads to p53
stabilization. The absence of p53 and/or Arf expression sup-
presses this phenotype and increases the chances of cellular
transformation (12). Moreover, Arf inhibits Myc through di-
rect binding, independently of its function on p53 (29). There-
fore, to investigate the functions of Arf that are p53 indepen-
dent, we ectopically expressed c-Myc in p53/ and double-
knockout MEFs. Expression of Myc in p53/ MEFs increased
the rate of cell proliferation (Fig. 6A) and induced their on-
cogenic conversion, as measured by the ability of Myc-express-
ing cells to form colonies in semisolid medium (Fig. 6A). Com-
parable levels of overexpressed Myc (Fig. 6A) provoked, in the
double-knockout MEFs, a higher proliferation rate and in-
creased frequency of transformation (Fig. 6A). Notably, the
size of methylcellulose colonies formed by the double-knock-
protein levels in p53/ and double-knockout MEFs either under basal conditions or after infection with a GFP-NPM-expressing retrovirus
(NPM). Right panels: immunofluorescence analysis of GFP-NPM localization in double-knockout MEFs (green) and its effect on endogenous
p19Arf localization (red). (C) Left panel: p19Arf mRNA levels in p53/ and double-knockout MEFs evaluated by quantitative PCR analysis
(results are normalized against p53/ RNA). Right panel: Western blotting analysis of p19Arf protein stability in p53/ and double-knockout
MEFs. MEFs were treated with cycloheximide (chx) to block protein synthesis and analyzed at the indicated time points after wash-out. As an
internal control, the same lysates were probed with antibodies against tubulin, which is stable over the 24 h of the experimental procedure.
(D) Upper left panel: immunofluorescence analysis of double-knockout MEFs infected with a p19Arf-expressing retroviruses. Lower left panel:
Western blotting analysis of p19Arf protein levels in double-knockout and p53/ MEFs infected with a control retrovirus or a retrovirus expressing
p19Arf. Right panel: growth curves of p53/ and double-knockout MEFs infected with a control retrovirus or a retrovirus expressing p19Arf; 2 
104 cells were plated into six-well plates and counted at daily intervals. Numbers refer to the mean values of triplicate determinations.
(E) Evaluation of newly synthesized rRNA by pulse-chase labeling with [3H]uridine in uninfected double-knockout and p53/ MEFs (left panel)
or upon infection with a control retrovirus or with a p19Arf-expressing retrovirus (right panel). Double-knockout MEFs were treated with
5-fluorouracil (5FU), as indicated. The different rRNA species, as detected by autoradiography, are indicated between the two panels.
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out cells was considerably larger than that of the controls (Fig.
6A). Comparable results, in terms of transforming ability and
colony growth, have been obtained by infecting the same cells
with RasV12 (Fig. 5B). In the cases of both RasV12 and Myc,
oncogene-induced Arf stabilization was modest in the double-
knockout MEFs, and p19Arf levels remain markedly lower than
in the p53/ MEFs.
Taken together, these results indicate that, in the absence of
NPM, the p53-independent effects of Arf on cellular proliferation
are less potent, either under basal conditions or after oncogenic
stimuli, likely due to reduced stability of the Arf protein.
DISCUSSION
We have demonstrated that the loss of NPM expression
provokes activation of a DNA damage response, suggesting
FIG. 6. Effects of NPM expression on transformation by Myc and Ras. (A) p53/ and double-knockout (KO) MEFs were infected with a
control retrovirus or a retrovirus expressing the c-myc oncogene. At the end of the selection, 2  104 cells were plated into six-well plates and cells
were counted at daily intervals. The numbers refer to the mean values of triplicate determinations. The same cells were analyzed by Western
blotting using antibodies against tubulin, p19Arf and Myc (right upper panel) and plated in semisolid medium (in triplicate). The number of colonies
(right lower panel) and representative plates and colonies (left lower panels) are shown. (C) Same experiment as described for panel A, using a
retrovirus expressing the RasV12 oncogene. We evaluated tubulin and p19Arf protein levels (right upper panel) and numbers of colonies formed
after plating in semisolid medium (left panel). Representative colonies are also shown (right lower panel).
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that one physiological function of NPM is to ensure DNA
integrity. This is consistent with earlier work showing the in-
volvement of NPM in the process of DNA repair after treat-
ment with different DNA-damaging agents, including UV light
(41). How NPM participates in DNA repair is not fully under-
stood. NPM is part of a multiprotein complex that possesses
DNA recombination activity on immunoglobulin heavy-chain
switch region sequences (5). In vitro, NPM promotes DNA
single-strand reannealing and mediates D-loop formation (5),
suggesting that it may participate in the first steps of a recom-
bination reaction (pairing of DNA substrates, strand invasion,
and formation of stable joint molecules). Alternatively, NPM
might function as a histone chaperone after DNA lesions are
repaired, during the assembly of new nucleosomes. In fact,
NPM binds histones and favors nucleosome assembly in vitro
(26).
Due to accumulation of damaged DNA, cells lacking NPM
activate a DNA damage response, which involves p53 activa-
tion and leads to senescence or apoptosis. In fact, fibroblasts
explanted from NPM/ embryos undergo growth arrest when
grown in culture, while fibroblasts from p53/ NPM/ em-
bryos can be easily propagated in culture. The availability of
double-knockout fibroblasts allowed us to investigate the effect
of NPM expression on cellular growth. Clearly, NPM expres-
sion is not critical for ribogenesis and cell proliferation. Dou-
ble-knockout fibroblasts grow faster than control cells and are
more susceptible to transformation by activated oncogenes,
such as RasV12 or c-myc. Notably, we also found increased
numbers of proliferating cells in the NPM/ embryos, sug-
gesting that one additional function of NPM is to inhibit cel-
lular proliferation.
The inhibitory effect exerted by NPM on cell proliferation
might be mediated by Arf. Arf protein is polyubiquitinated at
its N terminus and its degradation depends on the ubiquitin-
proteasome pathway (21). NPM binds the Arf protein and
protects it from degradation (21). Indeed, the stability of Arf
protein is markedly decreased in cells that lack NPM expres-
sion. However, inhibition of the proteasome only partially re-
stores the stability of p19Arf mutants that do not bind NPM
(21), suggesting that NPM protects Arf from both proteasome-
dependent and -independent degradation.
The amino-terminal region of Arf is dynamically disordered
in aqueous solution and becomes highly structured upon bind-
ing to Mdm2, suggesting that, in vivo, Arf is an intrinsically
unstructured protein that folds on binding to its biological
substrates (6). NPM might bind newly synthesized Arf and
serve as a molecular chaperone to favor acquisition of a ter-
tiary and stable structure, thus preventing its degradation or
aggregation.
However, when complexed to NPM, Arf maintains a free N
terminus and can be ubiquitinated (21). The leukemia-associ-
ated NPM mutant retains the ability to interact with Arf, but it
fails to prevent its degradation. Notably, this mutant is unable
to enter the nucleus and localizes mainly in the cytoplasm,
suggesting that one mechanism through which NPM protects
Arf from degradation is by ensuring its proper nucleolar or
nucleoplasmic localization.
Whether these two activities of NPM, regulation of DNA
integrity and of Arf protein stability, are functionally linked
remains unknown. DNA-damaging agents provoke the mobi-
lization of nucleolar NPM into the nucleoplasm (22), and its
binding to chromatin (28). Oncogene expression induces up-
regulation of Arf and, like the DNA-damaging agents, the
partial nucleoplasmic mobilization of NPM (9). NPM, in turn,
is indispensable for the full stabilization of Arf proteins after
oncogene expression. Recent findings indicate that oncogene-
driven cell divisions induce a DNA damage response which
might be responsible for activation of the Arf-p53 pathway
after oncogene expression (2). Thus, NPM might function as
specialized chaperone in the cellular response to DNA dam-
age, to coordinate arrest of cell proliferation and DNA repair
through its effects on Arf stability and chromatin, respectively.
Regardless of the underlying molecular mechanisms, these
activities of NPM might be relevant for the inherent ability of
cells to suppress transformation. NPM is frequently mutated in
leukemias (13) and lymphomas (24), suggesting that inactiva-
tion of the putative NPM tumor suppressor activities might be
critical for transformation. The leukemia-associated NPM mu-
tant competes with wild-type NPM in binding Arf, is unable to
protect it from degradation, and provokes its delocalization in
the cytoplasm (submitted for publication). Thus, in leukemias
carrying a mutated NPM allele, the levels of Arf protein are
decreased and the protein itself is delocalized, suggesting that
mutations of NPM lead to functional inactivation of the Arf
tumor suppressor pathway.
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